The Future of Cardiovascular Regenerative Medicine.
From Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, and the Harvard Stem Cell Institute and Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA (R.T.L.); and Whitaker Cardiovascular Institute, Boston University, Boston, MA (K.W.). RLee@partners.org kxwalsh@bu.edu.
Richard T
RT
Lee
From Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, and the Harvard Stem Cell Institute and Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA (R.T.L.); and Whitaker Cardiovascular Institute, Boston University, Boston, MA (K.W.). RLee@partners.org kxwalsh@bu.edu.
Kenneth
K
Walsh
D000818:Animals; D002309:Cardiology / Q000639:trends*; D002318:Cardiovascular Diseases / Q000235:genetics / Q000473:pathology / Q000503:physiopathology / Q000601:surgery*; D004059:Diffusion of Innovation; D005544:Forecasting; D015316:Genetic Therapy / Q000639:trends*; D006801:Humans; D009206:Myocardium / Q000473:pathology*; D020127:Recovery of Function; D012038:Regeneration; D044968:Regenerative Medicine / Q000639:trends*; D033581:Stem Cell Transplantation / Q000009:adverse effects / Q000639:trends*; D023822:Tissue Engineering / Q000639:trends*
genetics; heart failure; pharmaceutical preparations